Home > Insider Trading > Filing (0000899243-21-008691)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1326190	Altimmune Inc.	ALT	Pharmaceutical Preparations (2834)	202726770

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1705562	Philip Hodges	C/O Altimmune, Inc., 910 Clopper Road, Suite 201S Gaithersburg MD 20878		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001	Disposition	2021-03-01	6,000	$16.08	8,731	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001	17,848	Indirect	See Footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.56, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The shares of Common Stock are owned directly by Paradigm Venture Partners, L.P. The reporting person has sole voting and dispositive control with respect to all securities held by Paradigm Venture Partners, L.P. and may be deemed to be the beneficial owner of the securities held by Paradigm Venture Partners, L.P. The reporting person disclaims beneficial ownership of the securities held by Paradigm Venture Partners, L.P. except to the extent of his pecuniary interest therein.